[ad_1]
It was decided that clinical trials of the new type of corona virus (Covid-19) vaccine developed jointly by the University of Oxford and the pharmaceutical company AstraZeneca will continue after the break.
In the statement made by the University of Oxford, it was recalled that the studies were interrupted due to a disease that occurred in a volunteer.
It was stated that investigations on the subject have been completed and trials will start again in the UK following recommendations from both the independent safety review committee and the Medicines and Healthcare Products Regulatory Agency.
Oxford University’s Covid-19 vaccine trials were suspended on Sunday due to a negative reaction in a volunteer. The New York Times newspaper claimed that a trial participant in England developed transverse myelitis (inflammation of the spinal cord).
AstraZeneca reported that procedures for an independent committee to review the situation were suspended, which is often the case in vaccine studies.
Stage three trials of the candidate vaccine, which will be administered in multiple doses, are underway in the United Kingdom, the United States, Brazil, South Africa and India.
While the third stage is considered the last stage before approval, tens of thousands of vaccine candidates have so far been tested in England, Brazil and South Africa.
EVERYTHING YOU WANT TO KNOW ABOUT THE COVID-19 VACCINE
